Several of the highly effective treatment options for CRC patients are designed for patients with specific mutations (i.e. KRAS, EGFR, VEGF) or specifically target the immune system, however these approaches are not effective in the majority of CRC patients15. This evidence concerns the gene KRAS and colorectal carcinoma.